Evidence map›Paper›PMID 38201839›Full record

ArticleNutrients2023

Berberine Mediates the Production of Butyrate to Ameliorate Cerebral Ischemia via the Gut Microbiota in Mice.

Huijie Duan, Junya Hu, Yang Deng, Junqing Zou, Wangli Ding, Qiang Peng, Rui Duan, Jianguo Sun, Junrong Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Huijie DuanDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing 210006, China.
Junya HuDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing 210006, China.
Yang DengDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing 210006, China.ORCID 0000-0001-8655-2268
Junqing ZouDepartment of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Wangli DingDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing 210006, China.
Qiang PengDepartment of Neurology, Nanjing First Hospital, Nanjing 210006, China.
Rui DuanDepartment of Neurology, Nanjing First Hospital, Nanjing 210006, China.
Jianguo SunKey Lab of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0003-4417-7644
Junrong ZhuDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing 210006, China.
China Pharmaceutical University · CNNanjing Medical University · CN

Funding

Jianguo Sun BK20201117
6 · The paper itself

Abstract

Ischemic stroke (IS) is a vascular disease group concomitant with high morbidity and mortality. Berberine is a bioactive substance and it has been known to improve stroke, but its mechanism is yet to be proven. Mice were fed with BBR for 14 days. Then, the mice were made into MCAO/R models. Neurological score, infarct volume, neuronal damage and markers associated with inflammation were detected. We tested the changes in intestinal flora in model mice after BBR administration using 16SrRNA sequencing. Chromatography-mass spectrometry was used to detect butyrate chemically. Tissue immunofluorescence was used to detect the changes in the microglia and astroglia in the mice brains. Our findings suggest that berberine improves stroke outcomes by modulating the gut microbiota. Specifically, after MCAO/R mice were given berberine, the beneficial bacteria producing butyric acid increased significantly, and the mice also had significantly higher levels of butyric acid. The administration of butyric acid and an inhibitor of butyric acid synthesis, heptanoyl-CoA, showed that butyric acid improved the stroke outcomes in the model mice. In addition, butyric acid could inhibit the activation of the microglia and astrocytes in the brains of model mice, thereby inhibiting the generation of pro-inflammatory factors IL-6, IL-1β and TNF-α as well as improving stroke outcomes. Our results suggest that berberine may improve stroke outcomes by modulating the gut flora to increase the abundance of butyric acid. These findings elucidate the mechanisms by which berberine improves stroke outcomes and provide some basis for clinical treatment.

Indexed as

BerberineBrain IschemiaGastrointestinal MicrobiomeStrokeAnimalsButyric AcidMiceBerberineButyric Acidastrocytesbutyric acidgut microbiotamicrogliaNLRP3stroke

Identifiers

PMID38201839
PMCPMC10781073
OpenAlexW4390006675

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.